Cargando…

[(64)Cu]NOTA-pentixather enables high resolution PET imaging of CXCR4 expression in a preclinical lymphoma model

BACKGROUND: The chemokine receptor 4 (CXCR4) is an important molecular target for both visualization and therapy of tumors. The aim of the present study was the synthesis and preclinical evaluation of a (64)Cu-labeled, CXCR4-targeting peptide for positron emission tomography (PET) imaging of CXCR4 e...

Descripción completa

Detalles Bibliográficos
Autores principales:	Poschenrieder, Andreas, Schottelius, Margret, Osl, Theresa, Schwaiger, Markus, Wester, Hans-Jürgen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835975/ https://www.ncbi.nlm.nih.gov/pubmed/29527563 http://dx.doi.org/10.1186/s41181-016-0020-6

Ejemplares similares

[(177)Lu]pentixather: Comprehensive Preclinical Characterization of a First CXCR4-directed Endoradiotherapeutic Agent
por: Schottelius, Margret, et al.
Publicado: (2017)

A new class of PentixaFor- and PentixaTher-based theranostic agents with enhanced CXCR4-targeting efficiency
por: Osl, Theresa, et al.
Publicado: (2020)

Preclinical evaluation of [(68)Ga]NOTA-pentixafor for PET imaging of CXCR4 expression in vivo — a comparison to [(68)Ga]pentixafor
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

First (18)F-Labeled Pentixafor-Based Imaging Agent for PET Imaging of CXCR4 Expression In Vivo
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

The influence of different metal-chelate conjugates of pentixafor on the CXCR4 affinity
por: Poschenrieder, Andreas, et al.
Publicado: (2016)

Synthesis and evaluation of (64)Cu-radiolabeled NOTA-cetuximab ((64)Cu-NOTA-C225) for immuno-PET imaging of EGFR expression
por: Xu, Xiaoxia, et al.
Publicado: (2019)

Effect of Carbohydration on the Theranostic Tracer PSMA I&T
por: Schmidt, Alexander, et al.
Publicado: (2018)

Synthesis and preclinical evaluation of DOTAGA-conjugated PSMA ligands for functional imaging and endoradiotherapy of prostate cancer
por: Weineisen, Martina, et al.
Publicado: (2014)

CXCR4 expression in glioblastoma tissue and the potential for PET imaging and treatment with [(68)Ga]Ga-Pentixafor /[(177)Lu]Lu-Pentixather
por: Jacobs, Sarah M., et al.
Publicado: (2021)

Comparison of the Effects of DOTA and NOTA Chelators on (64)Cu-Cudotadipep and (64)Cu-Cunotadipep for Prostate Cancer
por: Lee, Inki, et al.
Publicado: (2023)

Twins in spirit - episode I: comparative preclinical evaluation of [(68)Ga]DOTATATE and [(68)Ga]HA-DOTATATE
por: Schottelius, Margret, et al.
Publicado: (2015)

(64)Cu-Labeled Ubiquitin for PET Imaging of CXCR4 Expression in Mouse Breast Tumor
por: Li, Huiqiang, et al.
Publicado: (2019)

Validation of [(125)I]CPCR4.3 as an investigative tool for the sensitive and specific detection of hCXCR4 and mCXCR4 expression in vitro and in vivo
por: Schottelius, Margret, et al.
Publicado: (2019)

In Vivo Targeting of CXCR4—New Horizons
por: Schottelius, Margret, et al.
Publicado: (2021)

CXCR4-directed theranostics in oncology and inflammation
por: Kircher, Malte, et al.
Publicado: (2018)

Synthesis and preclinical evaluation of novel (18)F-labeled Glu-urea-Glu-based PSMA inhibitors for prostate cancer imaging: a comparison with (18)F-DCFPyl and (18)F-PSMA-1007
por: Robu, Stephanie, et al.
Publicado: (2018)

(64)Cu-ATSM/(64)Cu-Cl(2) and their relationship to hypoxia in glioblastoma: a preclinical study
por: Pérès, Elodie A., et al.
Publicado: (2019)

Disclosing the CXCR4 Expression in Lymphoproliferative Diseases by Targeted Molecular Imaging
por: Wester, Hans Jürgen, et al.
Publicado: (2015)

Comparative Evaluation of Anti-HER2 Affibody Molecules Labeled with (64)Cu Using NOTA and NODAGA
por: Tolmachev, Vladimir, et al.
Publicado: (2017)

Monitoring CD8a(+) T Cell Responses to Radiotherapy and CTLA-4 Blockade Using [(64)Cu]NOTA-CD8a PET Imaging
por: Kristensen, Lotte K., et al.
Publicado: (2020)

Design, Synthesis, and Cytotoxicity Assessment of [(64)Cu]Cu-NOTA-Terpyridine Platinum Conjugate: A Novel Chemoradiotherapeutic Agent with Flexible Linker
por: Khosravifarsani, Meysam, et al.
Publicado: (2021)

Escuelas de las dobles notas Op. 64 : para piano /
por: Moszkowski, Moritz, 1854.1925
Publicado: (1978)

PET imaging of CXCR4 using copper-64 labeled peptide antagonist
por: Jacobson, Orit, et al.
Publicado: (2011)

[(64)Cu]Cu-DOTATATE PET metrics in the investigation of atherosclerotic inflammation in humans
por: Jensen, Jacob K., et al.
Publicado: (2022)

Influence of corticosteroid treatment on CXCR4 expression in DLBCL
por: Martin, Sebastian, et al.
Publicado: (2023)

Synthesis and in vitro and in vivo evaluation of urea-based PSMA inhibitors with increased lipophilicity
por: Wirtz, Martina, et al.
Publicado: (2018)

Positron Emission Tomography Imaging of CD105 Expression with a (64)Cu-Labeled Monoclonal Antibody: NOTA Is Superior to DOTA
por: Zhang, Yin, et al.
Publicado: (2011)

Pilot Study of (64)Cu(I) for PET Imaging of Melanoma
por: Jiang, Lei, et al.
Publicado: (2017)

(64)Cu-DOTATOC PET-CT in Patients with Neuroendocrine Tumors
por: Mirzaei, Siroos, et al.
Publicado: (2019)

Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET
por: Weiss, Ido D., et al.
Publicado: (2017)

PET imaging of chemokine receptor CXCR4 in patients with primary and recurrent breast carcinoma
por: Vag, Tibor, et al.
Publicado: (2018)

CXCR4 peptide-based fluorescence endoscopy in a mouse model of Barrett’s esophagus
por: Marcazzan, Sabrina, et al.
Publicado: (2022)

PET Imaging of the Neurotensin Targeting Peptide NOTA-NT-20.3 Using Cobalt-55, Copper-64 and Gallium-68
por: Houson, Hailey A., et al.
Publicado: (2022)

In vivo behavior of [(64)Cu]NOTA-terpyridine platinum, a novel chemo-radio-theranostic agent for imaging, and therapy of colorectal cancer
por: Khosravifarsani, Meysam, et al.
Publicado: (2022)

Correction: Screening of cancer tissue arrays identifies CXCR4 on adrenocortical carcinoma: correlates with expression and quantification on metastases using (64)Cu-plerixafor PET
por: Weiss, Ido D., et al.
Publicado: (2018)

Comparison of Immuno-PET of CD138 and PET imaging with (64)CuCl(2) and (18)F-FDG in a preclinical syngeneic model of multiple myeloma
por: Bailly, Clément, et al.
Publicado: (2018)

Pilot Study of (64)CuCl(2) for PET Imaging of Inflammation
por: Jiang, Lei, et al.
Publicado: (2018)

PET Imaging of VEGFR with a Novel (64)Cu-Labeled Peptide
por: Hu, Kuan, et al.
Publicado: (2020)

Comparative study of (64)Cu/NOTA-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14) monomer and dimers for prostate cancer PET imaging
por: Fournier, Patrick, et al.
Publicado: (2012)

Dual Targeting of Acute Leukemia and Supporting Niche by CXCR4-Directed Theranostics
por: Habringer, Stefan, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_dkt9karkgio1e5c4rrbn3b476c